0.9 Percent Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container by Baxter: Recall - Particulate Matter

Subject: FDA MedWatch - 0.9 Percent Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container by Baxter: Recall - Particulate Matter

<http://www.fda.gov/ucm/groups/fdagov-public/documents/image/ucm052224.gif> http://www.fda.gov/ucm/groups/fdagov-public/documents/image/ucm162880.gif

0.9 Percent Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container by Baxter:

Recall - Particulate Matter

AUDIENCE: Risk Manager, Pharmacy, Nursing

ISSUE: Baxter International Inc. initiated a recall in the United States of two lots of 0.9% Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container to the hospital/user level.

The recall is being initiated as a result of two complaints (one per lot) of particulate matter that was identified as a fragment of the frangible from the vial adapter. The issue was identified upon standard visual inspection prior to patient administration. This recall affects lot numbers P317842 and P317891.

Intravenous administration of a solution containing sterile particulate matter may lead to adverse health consequences. The extent and severity of harm depends on the size, number, and composition of the foreign material, and the patient's underlying medical condition. In the absence of in-line filtration, particles may cause: local vein irritation, inflammatory reaction, aggravation of preexisting infections, allergic reactions, and systemic embolization (blockage of blood vessels, which can result in stroke, heart attack, or damage to other organs such as the kidney or liver).

BACKGROUND: 0.9% Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container is a sterile, nonpyrogenic solution for intravenous administration after admixture with a single dose powdered drug.

RECOMMENDATION: According to the 0.9% Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container product labeling, the product should be inspected visually for particulate matter and discoloration whenever solution and container permit. Baxter has notified customers, who are being directed not to use product from the recalled lots.

Recalled product should be returned to Baxter for credit by contacting Baxter Healthcare Center for Service at 1-888-229-0001, Monday through Friday, between the hours of 7:00 a.m. and 6:00 p.m., Central Time. Unaffected lots of product are available for replacement.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program: * Complete and submit the report Online: www.fda.gov/MedWatch/report.htm <http://links.govdelivery.com:80/track?type=click&enid=ZWFzPTEmbWFpbGluZ2lkPTIwMTQxMjE2LjM5NDE5NzgxJm1lc3NhZ2VpZD1NREItUFJELUJVTC0yMDE0MTIxNi4zOTQxOTc4MSZkYXRhYmFzZWlkPTEwMDEmc2VyaWFsPTE3MDIwMDQyJmVtYWlsaWQ9ZGpjMDhAaGVhbHRoLnN0YXRlLm55LnVzJnVzZXJpZD1kamMwOEBoZWFsdGguc3RhdGUubnkudXMmZmw9JmV4dHJhPU11bHRpdmFyaWF0ZUlkPSYmJg==&&&100&&&http://www.fda.gov/MedWatch/report.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery> *

Download form http://links.govdelivery.com:80/track?type=click&enid=ZWFzPTEmbWFpbGluZ2lkPTIwMTQxMjE2LjM5NDE5NzgxJm1lc3NhZ2VpZD1NREItUFJELUJVTC0yMDE0MTIxNi4zOTQxOTc4MSZkYXRhYmFzZWlkPTEwMDEmc2VyaWFsPTE3MDIwMDQyJmVtYWlsaWQ9ZGpjMDhAaGVhbHRoLnN0YXRlLm55LnVzJnVzZXJpZD1kamMwOEBoZWFsdGguc3RhdGUubnkudXMmZmw9JmV4dHJhPU11bHRpdmFyaWF0ZUlkPSYmJg==&&&101&&&http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 Read the MeDWatch safety alert, including a link to the press release, at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm426996.htm <http://links.govdelivery.com:80/track?type=click&enid=ZWFzPTEmbWFpbGluZ2lkPTIwMTQxMjE2LjM5NDE5NzgxJm1lc3NhZ2VpZD1NREItUFJELUJVTC0yMDE0MTIxNi4zOTQxOTc4MSZkYXRhYmFzZWlkPTEwMDEmc2VyaWFsPTE3MDIwMDQyJmVtYWlsaWQ9ZGpjMDhAaGVhbHRoLnN0YXRlLm55LnVzJnVzZXJpZD1kamMwOEBoZWFsdGguc3RhdGUubnkudXMmZmw9JmV4dHJhPU11bHRpdmFyaWF0ZUlkPSYmJg==&&&102&&&http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm426996.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery> ________________________________

You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm <http://links.govdelivery.com:80/track?type=click&enid=ZWFzPTEmbWFpbGluZ2lkPTIwMTQxMjE2LjM5NDE5NzgxJm1lc3NhZ2VpZD1NREItUFJELUJVTC0yMDE0MTIxNi4zOTQxOTc4MSZkYXRhYmFzZWlkPTEwMDEmc2VyaWFsPTE3MDIwMDQyJmVtYWlsaWQ9ZGpjMDhAaGVhbHRoLnN0YXRlLm55LnVzJnVzZXJpZD1kamMwOEBoZWFsdGguc3RhdGUubnkudXMmZmw9JmV4dHJhPU11bHRpdmFyaWF0ZUlkPSYmJg==&&&103&&&http://www.fda.gov/medwatch/report.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery> Follow MedWatch on Twitter <http://links.govdelivery.com:80/track?type=click&enid=ZWFzPTEmbWFpbGluZ2lkPTIwMTQxMjE2LjM5NDE5NzgxJm1lc3NhZ2VpZD1NREItUFJELUJVTC0yMDE0MTIxNi4zOTQxOTc4MSZkYXRhYmFzZWlkPTEwMDEmc2VyaWFsPTE3MDIwMDQyJmVtYWlsaWQ9ZGpjMDhAaGVhbHRoLnN0YXRlLm55LnVzJnVzZXJpZD1kamMwOEBoZWFsdGguc3RhdGUubnkudXMmZmw9JmV4dHJhPU11bHRpdmFyaWF0ZUlkPSYmJg==&&&104&&&http://twitter.com/FDAMedWatch?source=govdelivery&utm_medium=email&utm_source=govdelivery> <http://www.fda.gov/ucm/groups/fdagov-public/documents/image/ucm218537.png>